Free Trial
→ Skip the Line Opportunity: The SpaceX IPO (From Brownstone Research) (Ad)tc pixel
NASDAQ:IBIO

iBio Q1 2025 Earnings Report

iBio logo
$1.94 +0.10 (+5.16%)
As of 12:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

iBio EPS Results

Actual EPS
-$0.46
Consensus EPS
-$0.46
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

iBio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

iBio Announcement Details

Quarter
Q1 2025
Date
11/12/2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
4:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

iBio's Q1 2025 Press ReleasePress Release
(8-K)
iBio's Q1 2025 Quarterly reportQuarterly report
(10-Q)

iBio Earnings Headlines

iBio to Participate in Upcoming Healthcare Investor Conferences
June 2 at 4:01 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3305569/0/en/ibio-to-participate-in-upcoming-healthcare-investor-conferences.html
iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
June 2 at 8:17 AM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68657523-ibio-inc-ibio-becomes-a-clinical-stage-company-with-first-participant-dosed-in-phase-1-clinical-trial-of-ibio-600-in-adults-with-obesity-399.htm
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
June 4 at 1:00 AM  |  Reagan Gold Group (Ad)
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
June 2 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3304990/0/en/ibio-becomes-a-clinical-stage-company-with-first-participant-dosed-in-phase-1-clinical-trial-of-ibio-600-in-adults-with-obesity.html
iBio (NASDAQ:IBIO) Stock Rating Upgraded by Wall Street Zen
May 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30808386
iBio, Inc. (NASDAQ:IBIO) Receives Average Recommendation of "Buy" from Analysts
May 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30801130
See More iBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email.

About iBio

iBio (NASDAQ:IBIO), a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

View iBio Profile
Earnings Tools